News >

Marrow Clearance With Concurrent CAR T-Cells, Ibrutinib in Resistant CLL

Published: Wednesday, Jun 07, 2017

Saar Gill, MD

Saar Gill, MD

Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia (CLL), results of a pilot study showed.

“Another important aspect of what we showed in this study is the relative lack of toxicity,” he added. “Everyone gets CRS but no one gets severe CRS. No patient required tocilizumab. Some of these patients were treated exclusively as outpatients. It is an advance, as far as I see.”
Gill S, Frey NV, Hexner EO, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol 35, 2017 (suppl; abstr 7509).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x